Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Share-based Compensation (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Share-based Compensation for 16 consecutive years, with $4399.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 39.83% year-over-year to $4399.0, compared with a TTM value of $35079.0 through Oct 2025, down 26.22%, and an annual FY2025 reading of $35079.0, down 26.22% over the prior year.
  • Share-based Compensation was $4399.0 for Q4 2025 at Pharma-Bio Serv, down from $9999.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $28445.0 in Q4 2022 and bottomed at $684.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $12779.6, with a median of $14399.5 recorded in 2022.
  • The sharpest move saw Share-based Compensation tumbled 97.6% in 2023, then skyrocketed 359.94% in 2024.
  • Year by year, Share-based Compensation stood at $21949.0 in 2021, then rose by 29.6% to $28445.0 in 2022, then crashed by 97.6% to $684.0 in 2023, then surged by 359.94% to $3146.0 in 2024, then skyrocketed by 39.83% to $4399.0 in 2025.
  • Business Quant data shows Share-based Compensation for PBSV at $4399.0 in Q4 2025, $9999.0 in Q3 2025, and $10000.0 in Q2 2025.